Advice
Product overview
Product overview
The content of this evidence summary was up to date in May 2021. See summaries of product characteristics (SPCs), British national formulary (BNF) or the Medicines and Healthcare products Regulatory Agency (MHRA) or NICE websites for up-to-date information.
Nebulised liposomal amikacin (amikacin liposomal nebuliser dispersion, Arikayce, Insmed) is an aminoglycoside antibiotic that is given by oral nebulisation once daily. It has a marketing authorisation for the treatment of non‑tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex in adults with limited treatment options, who do not have cystic fibrosis.